君实生物(01877.HK)JS203联合化疗III期临床研究完成首例患者给药

阿斯达克财经
Oct 26

君实生物(01877.HK) (688180.SH) 公布,产品重组人源化抗CD20和CD3双特异性抗体(JS203)联合化疗对比利妥昔单抗联合化疗在复发或难治性弥漫大B细胞淋巴瘤(DLBCL)患者中的随机、开放性、多中心III期临床研究已完成首例患者给药。该研究为JS203首个注册临床研究。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2026-10-23 16:25。) (A股报价延迟...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10